C-myc amplification in breast cancer: A meta-analysis of its occurrence and prognostic relevance

S. L. Deming, S. J. Nass, R. B. Dickson, Bruce Trock

Research output: Contribution to journalArticle

Abstract

Data from basic research suggests that amplification of the proto-oncogene c-myc is important in breast cancer pathogenesis, but its frequency of amplification and prognostic relevance in human studies have been inconsistent. In an effort to clarify the clinical significance of c-myc amplification in breast cancer, we conducted a comprehensive literature search and a meta-analysis in which 29 studies were evaluated. The weighted average frequency of c-myc amplification in breast tumours was 15.7% (95% CI = 12.5-18.8%), although estimates in individual studies exhibited significant heterogeneity, P <0.0001. C-myc amplification exhibited significant but weak associations with tumour grade (RR = 1.61), lymph-node metastasis (RR = 1.24), negative progesterone receptor status (RR = 1.27), and postmenopausal status (RR = 0.82). Amplification was significantly associated with risk of relapse and death, with pooled estimates RR = 2.05 (95% CI = 1.51-2.78) and RR = 1.74 (95% CI = 1.27-2.39), respectively. This effect did not appear to be merely a surrogate for other prognostic factors. These results suggest that c-myc amplification is relatively common in breast cancer and may provide independent prognostic information. More rigorous studies with consistent methodology are required to validate this association, and to investigate its potential as a molecular predictor of specific therapy response. (C) 2000 Cancer Research Campaign.

Original languageEnglish (US)
Pages (from-to)1688-1695
Number of pages8
JournalBritish Journal of Cancer
Volume83
Issue number12
DOIs
StatePublished - 2000
Externally publishedYes

Fingerprint

Meta-Analysis
Breast Neoplasms
myc Genes
Progesterone Receptors
Lymph Nodes
Neoplasm Metastasis
Recurrence
Research
Neoplasms
Therapeutics

Keywords

  • Amplification
  • Breast cancer
  • C-myc
  • Meta-analysis
  • Prognostic markers

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

C-myc amplification in breast cancer : A meta-analysis of its occurrence and prognostic relevance. / Deming, S. L.; Nass, S. J.; Dickson, R. B.; Trock, Bruce.

In: British Journal of Cancer, Vol. 83, No. 12, 2000, p. 1688-1695.

Research output: Contribution to journalArticle

Deming, S. L. ; Nass, S. J. ; Dickson, R. B. ; Trock, Bruce. / C-myc amplification in breast cancer : A meta-analysis of its occurrence and prognostic relevance. In: British Journal of Cancer. 2000 ; Vol. 83, No. 12. pp. 1688-1695.
@article{1a2ddee74ab54594afc91853fb27361b,
title = "C-myc amplification in breast cancer: A meta-analysis of its occurrence and prognostic relevance",
abstract = "Data from basic research suggests that amplification of the proto-oncogene c-myc is important in breast cancer pathogenesis, but its frequency of amplification and prognostic relevance in human studies have been inconsistent. In an effort to clarify the clinical significance of c-myc amplification in breast cancer, we conducted a comprehensive literature search and a meta-analysis in which 29 studies were evaluated. The weighted average frequency of c-myc amplification in breast tumours was 15.7{\%} (95{\%} CI = 12.5-18.8{\%}), although estimates in individual studies exhibited significant heterogeneity, P <0.0001. C-myc amplification exhibited significant but weak associations with tumour grade (RR = 1.61), lymph-node metastasis (RR = 1.24), negative progesterone receptor status (RR = 1.27), and postmenopausal status (RR = 0.82). Amplification was significantly associated with risk of relapse and death, with pooled estimates RR = 2.05 (95{\%} CI = 1.51-2.78) and RR = 1.74 (95{\%} CI = 1.27-2.39), respectively. This effect did not appear to be merely a surrogate for other prognostic factors. These results suggest that c-myc amplification is relatively common in breast cancer and may provide independent prognostic information. More rigorous studies with consistent methodology are required to validate this association, and to investigate its potential as a molecular predictor of specific therapy response. (C) 2000 Cancer Research Campaign.",
keywords = "Amplification, Breast cancer, C-myc, Meta-analysis, Prognostic markers",
author = "Deming, {S. L.} and Nass, {S. J.} and Dickson, {R. B.} and Bruce Trock",
year = "2000",
doi = "10.1054/bjoc.2000.1522",
language = "English (US)",
volume = "83",
pages = "1688--1695",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "12",

}

TY - JOUR

T1 - C-myc amplification in breast cancer

T2 - A meta-analysis of its occurrence and prognostic relevance

AU - Deming, S. L.

AU - Nass, S. J.

AU - Dickson, R. B.

AU - Trock, Bruce

PY - 2000

Y1 - 2000

N2 - Data from basic research suggests that amplification of the proto-oncogene c-myc is important in breast cancer pathogenesis, but its frequency of amplification and prognostic relevance in human studies have been inconsistent. In an effort to clarify the clinical significance of c-myc amplification in breast cancer, we conducted a comprehensive literature search and a meta-analysis in which 29 studies were evaluated. The weighted average frequency of c-myc amplification in breast tumours was 15.7% (95% CI = 12.5-18.8%), although estimates in individual studies exhibited significant heterogeneity, P <0.0001. C-myc amplification exhibited significant but weak associations with tumour grade (RR = 1.61), lymph-node metastasis (RR = 1.24), negative progesterone receptor status (RR = 1.27), and postmenopausal status (RR = 0.82). Amplification was significantly associated with risk of relapse and death, with pooled estimates RR = 2.05 (95% CI = 1.51-2.78) and RR = 1.74 (95% CI = 1.27-2.39), respectively. This effect did not appear to be merely a surrogate for other prognostic factors. These results suggest that c-myc amplification is relatively common in breast cancer and may provide independent prognostic information. More rigorous studies with consistent methodology are required to validate this association, and to investigate its potential as a molecular predictor of specific therapy response. (C) 2000 Cancer Research Campaign.

AB - Data from basic research suggests that amplification of the proto-oncogene c-myc is important in breast cancer pathogenesis, but its frequency of amplification and prognostic relevance in human studies have been inconsistent. In an effort to clarify the clinical significance of c-myc amplification in breast cancer, we conducted a comprehensive literature search and a meta-analysis in which 29 studies were evaluated. The weighted average frequency of c-myc amplification in breast tumours was 15.7% (95% CI = 12.5-18.8%), although estimates in individual studies exhibited significant heterogeneity, P <0.0001. C-myc amplification exhibited significant but weak associations with tumour grade (RR = 1.61), lymph-node metastasis (RR = 1.24), negative progesterone receptor status (RR = 1.27), and postmenopausal status (RR = 0.82). Amplification was significantly associated with risk of relapse and death, with pooled estimates RR = 2.05 (95% CI = 1.51-2.78) and RR = 1.74 (95% CI = 1.27-2.39), respectively. This effect did not appear to be merely a surrogate for other prognostic factors. These results suggest that c-myc amplification is relatively common in breast cancer and may provide independent prognostic information. More rigorous studies with consistent methodology are required to validate this association, and to investigate its potential as a molecular predictor of specific therapy response. (C) 2000 Cancer Research Campaign.

KW - Amplification

KW - Breast cancer

KW - C-myc

KW - Meta-analysis

KW - Prognostic markers

UR - http://www.scopus.com/inward/record.url?scp=0034538306&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034538306&partnerID=8YFLogxK

U2 - 10.1054/bjoc.2000.1522

DO - 10.1054/bjoc.2000.1522

M3 - Article

C2 - 11104567

AN - SCOPUS:0034538306

VL - 83

SP - 1688

EP - 1695

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 12

ER -